|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Bellone S, Pecorelli S, Cannon MJ and
Santin AD: Advances in dendritic-cell-based therapeutic vaccines
for cervical cancer. Expert Rev Anticancer Ther. 7:1473–1486. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leitao MM and Chi DS: Recurrent cervical
cancer. Curr Treat Options Oncol. 3:105–111. 2002. View Article : Google Scholar
|
|
4
|
Friedlander M: Guidelines for the
treatment of recurrent and metastatic cervical cancer. Oncologist.
7:342–347. 2002.PubMed/NCBI
|
|
5
|
Quinn MA, Benedet JL, Odicino F,
Maisonneuve P, Beller U, Creasman WT, Heintz APM, Ngan HYS and
Pecorelli S: Carcinoma of the cervix uteri. Int J Gynecol Obstet.
95(Suppl 1): 43–103. 2006. View Article : Google Scholar
|
|
6
|
Dornhöfer N and Höckel M: New developments
in the surgical therapy of cervical carcinoma. Ann NY Acad Sci.
1138:233–252. 2008.
|
|
7
|
Höckel M: Pelvic recurrences of cervical
cancer. Relapse pattern, prognostic factors and the role of
extended radical treatment. J Pelv Surg. 5:255–266. 1999.
|
|
8
|
Zatoński W and Tyczyński J: Cancer in
Poland in 1993. Zakład Epidemiologii i Prewencji Nowotworów.
Krajowy Rejestr Nowotworów; Warszawa: pp. 22–41. 1996
|
|
9
|
Panek G, Gawrychowski K, Sobiczewski P,
Derlatka P, Danska-Bidzinska A, Gmyrek L and Bidzinski M: Results
of chemotherapy for pulmonary metastases of carcinoma of the cervix
in patients after primary surgical and radiotherapeutic management.
Int J Gynecol Cancer. 17:1056–1061. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zola P, Fuso L, Mazzola S, Piovano E,
Perotto S, Gadducci A, Galletto L, Landoni F, Maggino T,
Raspagliesi F, Sartori E and Scambia G: Could follow-up different
modalities play a role in asymptomatic cervical cancer relapses
diagnosis? An Italian multicenter retrospective analysis. Gynecol
Oncol. 107(Suppl 1): 150–154. 2007. View Article : Google Scholar
|
|
11
|
Potter ME, Alvarez RD, Gay FL, Shingleton
HM, Soong SJ and Hatch KD: Optimal therapy for pelvic recurrence
after radical hysterectomy for early-stage cervical cancer. Gynecol
Oncol. 37:74–77. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Malfetano J, Keys H, Kredentser D,
Cunningham M, Kotlove D and Weiss L: Weekly cisplatin and radical
radiation therapy for advanced, recurrent and poor prognosis
cervical carcinoma. Cancer. 71:3703–3706. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ijaz T, Eifel PJ, Burke T and Oswald MJ:
Radiation therapy of pelvic recurrence after radical hysterectomy
for cervical carcinoma. Gynecol Oncol. 70:241–246. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smaniotto D, D’Agostino G, Luzi S,
Valentini V, Macchia G, Mantini G, Margariti PA, Ferrandina G and
Scambia G: Concurrent 5-fluorouracil, mitomycin C and radiation
with or without brachytherapy in recurrent cervical cancer: a
scoring system to predict clinical response and outcome. Tumori.
91:295–301. 2005.
|
|
15
|
Windschall A, Ott OJ, Sauer R and Strnad
V: Radiation therapy and simultaneous chemotherapy for recurrent
cervical carcinoma. Strahlenther Onkol. 181:545–550. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miglietta L, Franzone P, Centurioni MG,
Boni L, Tacchini L, Cosso M, Boccardo F, Ferrarini M and Bruzzone
M: A phase II trial with cisplatin-paclitaxel cytotoxic treatment
and concurrent external and endocavitary radiation therapy in
locally advanced or recurrent cervical cancer. Oncology. 70:19–24.
2006. View Article : Google Scholar
|
|
17
|
Jain P, Hunter RD, Livsey JE, Coyle C,
Swindell R and Davidson SE: Salvaging locoregional recurrence with
radiotherapy after surgery in early cervical cancer. Clin Oncol (R
Coll Radiol). 19:763–768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Piura B, Rabinovich A and Friger M:
Recurrent cervical carcinoma after radical hysterectomy and pelvic
lymph node dissection: a study of 32 cases. Eur J Gynaecol Oncol.
29:31–36. 2008.PubMed/NCBI
|
|
19
|
Barter JF, Soong SJ, Shingleton HM, Hatch
KD and Orr JW Jr: Complications of combined radical
hysterectomy-postoperative radiation therapy in women with early
stage cervical cancer. Gynecol Oncol. 32:292–296. 1989. View Article : Google Scholar
|
|
20
|
Magrina JF: Complications of irradiation
and radical surgery for gynecologic malignancies. Obstet Gynecol
Surv. 48:571–575. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mundt AJ, Roeske JC, Lujan AE, Yamada SD,
Waggoner SE, Fleming G and Rotmensch J: Initial clinical experience
with intensity-modulated whole-pelvis radiation therapy in women
with gynecologic malignancies. Gynecol Oncol. 82:456–463. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Friedell GH, Cesare F and Parson L:
Surgical treatment of cancer of the cervix recurring after primary
irradiation therapy. N Engl J Med. 264:781–784. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rubin SC, Hoskins WJ and Lewis JL: Radical
hysterectomy for recurrent cervical cancer following radiation
therapy. Gynecol Oncol. 27:316–324. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Terada K and Morley GW: Radical
hysterectomy as surgical salvage therapy for gynecologic
malignancy. Obstet Gynecol. 70:913–915. 1987.PubMed/NCBI
|
|
25
|
Rutledge S, Carey MS, Prichard H, Allen
HH, Kocha W and Kirk ME: Conservative surgery for recurrent or
persistent carcinoma of the cervix following irradiation: is
exenteration always necessary? Gynecol Oncol. 52:353–359. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Coleman RL, Keeney ED, Freedman RS, Burke
TW, Eifel PJ and Rutledge FN: Radical hysterectomy for recurrent
carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol.
55:29–35. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maneo A, Landoni F, Cormio G, Colombo A
and Mangioni C: Radical hysterectomy for recurrent or persistent
cervical cancer following radiation therapy. Int J Gynecol Cancer.
9:295–301. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Magrina JF: Types of pelvic exenterations:
a reappraisal. Gynecol Oncol. 37:363–366. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Magrina JF, Stanhope CR and Weaver AL:
Pelvic exenterations: supralevator, infralevator, and with
vulvectomy. Gynecol Oncol. 64:130–135. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chiva LM, Lapuente F, González-Cortijo L,
González-Martín A, Rojo A, García JF and Carballo N: Surgical
treatment of recurrent cervical cancer: state of the art and new
achievements. Gynecol Oncol. 110(Suppl 2): 60–66. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brunschwig A and Barber HR: Extended
pelvic exenteration for advanced cancer of the cervix. Long
survivals following added resection of involved small bowel.
Cancer. 17:1267–1270. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kiselow M, Butcher HR Jr and Bricker EM:
Results of the radical surgical treatment of advanced pelvic
cancer: a fifteen-year study. Ann Surg. 166:428–436.
1967.PubMed/NCBI
|
|
33
|
Creasman WT and Rutledge F: Is positive
pelvic lymphadenopathy a contraindication to radical surgery in
recurrent cervical carcinoma? Gynecol Oncol. 2:482–485. 1974.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rutledge FN, Smith JP, Wharton JT and
O’Quinn AG: Pelvic exenteration: analysis of 296 patients. Am J
Obstet Gynecol. 129:881–892. 1977.PubMed/NCBI
|
|
35
|
Symmonds RE, Pratt JH and Webb MJ:
Exenterative operations: experience with 198 patients. Am J Obstet
Gynecol. 121:907–918. 1975.PubMed/NCBI
|
|
36
|
Karlen JR and Piver MS: Reduction of
mortality and morbidity associated with pelvic exenteration.
Gynecol Oncol. 3:164–167. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Morley GW, Hopkins MP, Lindenauer SM and
Roberts JA: Pelvic exenteration, University of Michigan: 100
patients at 5 years. Obstet Gynecol. 74:934–943. 1989.PubMed/NCBI
|
|
38
|
Shingleton HM, Soong SJ, Gelder MS, Hatch
KD, Baker VV and Austin JM Jr: Clinical and histopathologic factors
predicting recurrence and survival after pelvic exenteration for
cancer of the cervix. Obstet Gynecol. 73:1027–1034. 1989.PubMed/NCBI
|
|
39
|
Marnitz S, Köhler C, Müller M, Behrens K,
Hasenbein K and Schneider A: Indications for primary and secondary
exenterations in patients with cervical cancer. Gynecol Oncol.
103:1023–1030. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Goldberg GL, Sukumvanich P, Einstein MH,
Smith HO, Anderson PS and Fields AL: Total pelvic exenteration: the
Albert Einstein College of Medicine/Montefiore Medical Center
Experience (1987 to 2003). Gynecol Oncol. 101:261–268. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Berek JS, Howe C, Lagasse LD and Hacker
NF: Pelvic exenteration for recurrent gynecologic malignancy:
survival and morbidity analysis of the 45-year experience at UCLA.
Gynecol Oncol. 99:153–159. 2005.PubMed/NCBI
|
|
42
|
Crozier M, Morris M, Levenback C, Lucas
KR, Atkinson EN and Wharton JT: Pelvic exenteration for
adenocarcinoma of the uterine cervix. Gynecol Oncol. 58:74–78.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fleisch MC, Pantke P, Beckmann MW,
Schnuerch HG, Ackermann R, Grimm MO, Bender HG and Dall P:
Predictors for long-term survival after interdisciplinary salvage
surgery for advanced or recurrent gynecologic cancers. J Surg
Oncol. 95:476–484. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kinkel K, Ariche M, Tardivon AA, Spatz A,
Castaigne D, Lhomme C and Vanel D: Differentiation between
recurrent tumor and benign conditions after treatment of
gynecologic pelvic carcinoma: value of dynamic contrast-enhanced
subtraction MR imaging. Radiology. 204:55–63. 1997. View Article : Google Scholar
|
|
45
|
Popovich MJ, Hricak H, Sugimura K and
Stern JL: The role of MR imaging in determining surgical
eligibility for pelvic exenteration. AJR Am J Roentgenol.
160:525–531. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jeong YY, Kang HK, Chung TW, Seo JJ and
Park JG: Uterine cervical carcinoma after therapy: CT and MR
imaging findings. Radiographics. 23:969–981. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Elst P, Ahankour F and Tjalma W:
Management of recurrent cervical cancer. Review of the literature
and case report. Eur J Gynaecol Oncol. 28:435–441. 2007.PubMed/NCBI
|
|
48
|
Husain A, Akhurst T, Larson S, Alektiar K,
Barakat RR and Chi DS: A prospective study of the accuracy of
18fluorodeoxyglucose positron emission tomography (18FDG PET) in
identifying sites of metastasis prior to pelvic exenteration.
Gynecol Oncol. 106:177–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Babar S, Rockall A, Goode A, Shepherd J
and Reznek R: Magnetic resonance imaging appearances of recurrent
cervical carcinoma. Int J Gynecol Cancer. 17:637–645. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jover R, Lourido D, Gonzalez C, Rojo A,
Gorospe L and Alfonso JM: Role of PET/CT in the evaluation of
cervical cancer. Gynecol Oncol. 110(Suppl 2): 55–59. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Höckel M and Dornhöfer N: Pelvic
exenteration for gynaecologic tumours: achievements and unanswered
questions. Lancet Oncol. 7:837–847. 2006.
|
|
52
|
Plante M and Roy M: Operative laparoscopy
prior to a pelvic exenteration in patients with recurrent cervical
cancer. Gynecol Oncol. 69:94–99. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kohler C, Tozzi R, Possover M and
Schneider A: Explorative laparoscopy prior to exenterative surgery.
Gynecol Oncol. 86:311–315. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Stein P, Daneshmand S, Dunn M, Garcia M,
Lieskovsky G and Skinner DG: Continent right colon reservoir using
a cutaneous appendicostomy. Urology. 63:577–580. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Rowland RG and Kropp BP: Evolution of the
Indiana continent urinary reservoir. J Urol. 152:2247–2251.
1994.PubMed/NCBI
|
|
56
|
Bihrle R: The Indiana pouch continent
urinary reservoir. Urol Clin North Am. 24:773–779. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Salom EM, Mendez LE, Schey D, Lambrou N,
Kassira N, Gómez-Marn O, Averette H and Peñalver M: Continent
ileocolonic urinary reservoir (Miami pouch): the University of
Miami experience over 15 years. Am J Obstet Gynecol. 190:994–1003.
2004.PubMed/NCBI
|
|
58
|
Angioli R, Benedetti Panici P, Mirhashemi
R, Mendez L, Cantuaria G, Basile S and Penalver M: Continent
urinary diversion and low colorectal anastomosis after pelvic
exenteration. Quality of life and complication risk. Crit Rev Oncol
Hematol. 48:281–285. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Benedetti Panici P, Angioli R, Plotti F,
Muzii L, Zullo MA, Manci N, Palaia I and Galluci M: Continent
ileocolonic urinary diversion (Rome pouch) for gynecologic
malignancies: technique and feasibility. Gynecol Oncol.
107:194–199. 2007.PubMed/NCBI
|
|
60
|
Hatch KD, Gelder MS, Soong SJ, Baker VV
and Shingleton HM: Pelvic exenteration with low rectal anastomosis:
survival, complications, and prognostic factors. Gynecol Oncol.
38:462–467. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rietjens M, Maggioni A, Bocciolone L,
Sideri M, Youssef O and Petit JY: Vaginal reconstruction after
extended radical pelvic surgery for cancer: comparison of two
techniques. Plast Reconstr Surg. 109:1592–1599. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Green AE, Escobar PF, Neubaurer N,
Michener CM and Vongruenigen VE: The Martius flap neovagina
revisited. Int J Gynecol Cancer. 15:964–966. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
O’Connell C, Mirhashemi R, Kassira N,
Lambrou N and McDonald WS: Formation of functional neovagina with
vertical rectus abdominis musculocutaneous (VRAM) flap after total
pelvic exenteration. Ann Plast Surg. 55:470–473. 2005.PubMed/NCBI
|
|
64
|
Del Carmen MG, McIntyre JF and Goodman A:
The role of intraoperative radiation therapy (IORT) in the
treatment of locally advanced gynecologic malignancies. Oncologist.
5:18–25. 2000.PubMed/NCBI
|
|
65
|
Gemignani ML, Alektiar KM, Leitao M,
Mychalczak B, Chi D, Venkatraman E, Barakat RR and Curtin JP:
Radical surgical resection and high-dose intraoperative radiation
therapy (HDR-IORT) in patients with recurrent gynecologic cancers.
Int J Radiat Oncol Biol Phys. 50:687–694. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hicks ML, Piver MS, Mas E, Hempling RE,
Mcauley M and Walsh DL: Intraoperative orthovoltage radiation
therapy in the treatment of recurrent gynecologic malignancies. Am
J Clin Oncol. 16:497–500. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Höckel M: Laterally extended endopelvic
resection: novel surgical treatment of locally recurrent cervical
carcinoma involving the pelvic side wall. Gynecol Oncol.
91:369–377. 2003.
|
|
68
|
Höckel M: Laterally extended endopelvic
resection (LEER) – principles and practice. Gynecol Oncol.
111:S13–S17. 2008.
|
|
69
|
Lopez-Graniel C, Dolores R, Cetina L,
Gonzalez A, Cantu D, Chanona J, Uribe J, Candelaria M, Brom R, de
la Garza J and Duenas-Gonzalez A: Pre-exenterative chemotherapy, a
novel therapeutic approach for patients with persistent or
recurrent cervical cancer. BMC Cancer. 5:1182005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hogg R and Friedlander M: Role of systemic
chemotherapy in metastatic cervical cancer. Expert Rev Anticancer
Ther. 3:234–240. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tambaro R, Scambia G, di Maio M, Pisano C,
Barletta E, Iaffaioli VR and Pignata S: The role of chemotherapy in
locally advanced, metastatic and recurrent cervical cancer. Crit
Rev Oncol Hematol. 52:33–44. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Pectasides D, Kamposioras K, Papaxoinis G
and Pectasides E: Chemotherapy for recurrent cervical cancer.
Cancer Treat Rev. 34:603–613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Carl UM, Bahnsen J and Rapp W: Radiation
therapy of para-aortic lymph nodes in gynaecologic cancers:
techniques, results and complications. Strahlenther Onkol.
168:383–389. 1992.PubMed/NCBI
|
|
74
|
Grigsby PW, Vest ML and Perez CA:
Recurrent carcinoma of the cervix exclusively in the paraaortic
nodes following radiation therapy. Int J Radiat Oncol Biol Phys.
28:451–455. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Chou HH, Wang CC, Lai CH, Hong JH, Ng KK,
Chang TC, Tseng CJ, Tsai CS and Chang JT: Isolated paraaortic lymph
node recurrence after definitive irradiation for cervical
carcinoma. Int J Radiat Oncol Biol Phys. 51:442–448. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Singh AK, Grigsby PW, Rader JS, Mutch DG
and Powell MA: Cervix carcinoma, concurrent chemoradiotherapy and
salvage of isolated paraaortic lymph node recurrence. Int J Radiat
Oncol Biol Phys. 61:450–455. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kim JS, Kim JS, Kim SY, Kim KH and Cho MJ:
Hyperfractionated radiotherapy with concurrent chemotherapy for
para-aortic lymph node recurrence in carcinoma of the cervix. Int J
Radiat Oncol Biol Phys. 55:1247–1253. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
DuPont NC and Monk BJ: Chemotherapy in the
management of cervical carcinoma. Clin Adv Hematol Oncol.
4:279–286. 2006.PubMed/NCBI
|
|
79
|
Thigpen T, Shingleton H, Homesley H,
Lagasse L and Blessing J: Cisplatin in treatment of advanced or
recurrent squamous cell carcinoma of the cervix: a phase II study
of the Gynecologic Oncology Group. Cancer. 48:899–903. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Bonomi P, Blessing JA, Stehman FB, DiSaia
PJ, Walton L and Major FJ: Randomized trial of three cisplatin dose
schedules in squamous-cell carcinoma of the cervix: a Gynecologic
Oncology Group study. J Clin Oncol. 3:1079–1085. 1985.PubMed/NCBI
|
|
81
|
Thigpen JT, Blessing JA, Fowler WC Jr and
Hatch K: Phase II trials of cisplatin and piperazinedione as single
agents in the treatment of advanced or recurrent non-squamous cell
carcinoma of the cervix: a Gynecologic Oncology Group Study. Cancer
Treat Rep. 70:1097–1100. 1986.PubMed/NCBI
|
|
82
|
Thigpen JT, Blessing JA, DiSaia PJ, Fowler
WC Jr and Hatch KD: A randomized comparison of a rapid versus
prolonged (24 h) infusion of cisplatin in therapy of squamous cell
carcinoma of the uterine cervix: a Gynecologic Oncology Group
study. Gynecol Oncol. 32:198–202. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Lele SB and Piver MS: Weekly cisplatin
induction chemotherapy in the treatment of recurrent cervical
carcinoma. Gynecol Oncol. 33:6–8. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Potter ME, Hatch KD, Potter MY, Shingleton
HM and Baker VV: Factors affecting the response of recurrent
squamous cell carcinoma of the cervix to cisplatin. Cancer.
63:1283–1286. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Arseneau J, Blessing JA, Stehman FB and
McGehee R: A phase II study of carboplatin in advanced squamous
cell carcinoma of the cervix (a Gynecologic Oncology Group Study).
Invest New Drugs. 4:187–191. 1986.PubMed/NCBI
|
|
86
|
McGuire WP III, Arseneau J, Blessing JA,
DiSaia PJ, Hatch KD, Given FT Jr, Teng NN and Creasman WT: A
randomized comparative trial of carboplatin and iproplatin in
advanced squamous carcinoma of the uterine cervix: a Gynecologic
Oncology Group study. J Clin Oncol. 7:1462–1468. 1989.PubMed/NCBI
|
|
87
|
Weiss GR, Green S, Hannigan EV, Boutselis
JG, Surwit EA, Wallace DL and Alberts DS: A phase II trial of
carboplatin for recurrent or metastatic squamous carcinoma of the
uterine cervix: a Southwest Oncology Group study. Gynecol Oncol.
39:332–336. 1990. View Article : Google Scholar
|
|
88
|
Meanwell CA, Mould JJ, Blackledge G,
Lawton FG, Stuart NS, Kavanagh J, Latief TN, Spooner D and
Chetiyawardana AD: Phase II study of ifosfamide in cervical cancer.
Cancer Treat Rep. 70:727–730. 1986.PubMed/NCBI
|
|
89
|
Sutton GP, Blessing JA, Adcock L, Webster
KD and DeEulis T: Phase II study of ifosfamide and mesna in
patients with previously-treated carcinoma of the cervix: a
Gynecologic Oncology Group study. Invest New Drugs. 7:341–343.
1989.PubMed/NCBI
|
|
90
|
Sutton GP, Blessing JA, DiSaia PJ and
McGuire WP: Phase II study of ifosfamide and mesna in nonsquamous
carcinoma of the cervix: a Gynecologic Oncology Group study.
Gynecol Oncol. 49:48–50. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Rhomberg WU: Vindesine for recurrent and
metastatic cancer of the uterine cervix: a phase II study. Cancer
Treat Rep. 70:1455–1457. 1986.PubMed/NCBI
|
|
92
|
Morris M, Brader KR, Levenback C, Burke
TW, Atkinson EN, Scott WR and Gershenson DM: Phase II study of
vinorelbine in advanced and recurrent squamous cell carcinoma of
the cervix. J Clin Oncol. 16:1094–1098. 1998.PubMed/NCBI
|
|
93
|
Lhommé C, Vermorken JB, Mickiewicz E,
Chevalier B, Alvarez A, Mendiola C, Pawinski A, Lentz MA and
Pecorelli S: Phase II trial of vinorelbine in patients with
advanced and/or recurrent cervical carcinoma: an EORTC
Gynaecological Cancer Cooperative Group study. Eur J Cancer.
36:194–199. 2000.PubMed/NCBI
|
|
94
|
Muggia FM, Blessing JA, Waggoner S, Berek
JS, Monk BJ, Sorosky J and Pearl ML: Evaluation of vinorelbine in
persistent or recurrent nonsquamous carcinoma of the cervix: a
Gynecologic Oncology Group Study. Gynecol Oncol. 96:108–111. 2005.
View Article : Google Scholar
|
|
95
|
Schilder RJ, Blessing JA, Morgan M, Mangan
CE and Rader JS: Evaluation of gemcitabine in patients with
squamous cell carcinoma of the cervix: a phase II study of the
gynecologic oncology group. Gynecol Oncol. 76:204–207. 2000.
View Article : Google Scholar
|
|
96
|
Schilder RJ, Blessing J and Cohn DE:
Evaluation of gemcitabine in previously treated patients with
non-squamous cell carcinoma of the cervix: a phase II study of the
Gynecologic Oncology Group. Gynecol Oncol. 96:103–107. 2005.
View Article : Google Scholar
|
|
97
|
McGuire WP, Blessing JA, Moore D, Lentz SS
and Photopulos G: Paclitaxel has moderate activity in squamous
cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol.
14:792–795. 1996.PubMed/NCBI
|
|
98
|
Kudelka AP, Winn R, Edwards CL, Downey G,
Greenberg H, Dakhil SR, Freedman RS, Loyer E, Rusinkiewicz J,
Gacrama P, Fueger R and Kavanagh JJ: Activity of paclitaxel in
advanced or recurrent squamous cell cancer of the cervix. Clin
Cancer Res. 2:1285–1288. 1996.PubMed/NCBI
|
|
99
|
Kudelka AP, Winn R, Edwards CL, Downey G,
Greenberg H, Dakhil SR, Freedman RS, LoCoco S, Umbreit J, Delmore
JE, Arbuck S, Loyer E, Gacrama P, Fueger R and Kavanagh JJ: An
update of a phase II study of paclitaxel in advanced or recurrent
squamous cell cancer of the cervix. Anticancer Drugs. 8:657–661.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Curtin JP, Blessing JA, Webster KD, Rose
PG, Mayer AR, Fowler WC Jr, Malfetano JH and Alvarez RD:
Paclitaxel, an active agent in nonsquamous carcinomas of the
uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol.
19:1275–1278. 2001.PubMed/NCBI
|
|
101
|
Garcia AA, Blessing JA, Vaccarello L and
Roman LD: Gynecologic Oncology Group Study: phase II clinical trial
of docetaxel in refractory squamous cell carcinoma of the cervix: a
Gynecologic Oncology Group Study. Am J Clin Oncol. 30:428–431.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Bookman MA, Blessing JA, Hanjani P, Herzog
TJ and Andersen WA: Topotecan in squamous cell carcinoma of the
cervix: a phase II study of the Gynecologic Oncology Group. Gynecol
Oncol. 77:446–449. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Muderspach LI, Blessing JA, Levenback C
and Moore JL Jr: A Phase II study of topotecan in patients with
squamous cell carcinoma of the cervix: a Gynecologic Oncology Group
study. Gynecol Oncol. 81:213–215. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Verschraegen CF, Levy T, Kudelka AP,
Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M,
Kaplan AL, Kieback D, Fishman A and Kavanagh JJ: Phase II study of
irinotecan in prior chemotherapy-treated squamous cell carcinoma of
the cervix. J Clin Oncol. 15:625–631. 1997.PubMed/NCBI
|
|
105
|
Lhommé C, Fumoleau P, Fargeot P, Krakowski
Y, Dieras V, Chauvergne J, Vennin P, Rebattu P, Roche H, Misset JL,
Lentz MA, van Glabbeke M, Matthieu-Boué A, Mignard D and Chevallier
B: Results of a European Organization for Research and Treatment of
Cancer/Early Clinical Studies Group phase II trial of first-line
irinotecan in patients with advanced or recurrent squamous cell
carcinoma of the cervix. J Clin Oncol. 17:3136–3142.
1999.PubMed/NCBI
|
|
106
|
Goedhals L, van Wiyk AL, Smith BL and
Fourie SJ: Pemetrexed (Alimta, LY231514) demonstrates clinical
activity in chemonaive patients with cervical cancer in a phase II
single-agent trial. Int J Gynecol Cancer. 16:1172–1178. 2006.
View Article : Google Scholar
|
|
107
|
Miller DS, Blessing JA, Bodurka DC,
Bonebrake AJ and Schorge JO: Gynecologic Oncology Group: evaluation
of pemetrexed (Alimta, LY231514) as second line chemotherapy in
persistent or recurrent carcinoma of the cervix: a phase II study
of the Gynecologic Oncology Group. Gynecol Oncol. 110:65–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ferrandina G, Lorusso D, Ludovisi M,
Pignata S, Sorio R, Mangili G, Breda E, Legge F, Pisconti S and
Scambia G: Phase II study on pemetrexed in advanced/or recurrent
cervical cancer patients: a MITO study. J Oncol. 26(Suppl 296):
abs. 5515. 2008.
|
|
109
|
Bonomi P, Blessing J, Ball H, Hanjani P
and DiSaia PJ: A phase II evaluation of cisplatin and
5-fluorouracil in patients with advanced squamous cell carcinoma of
the cervix: a Gynecologic Oncology Group study. Gynecol Oncol.
34:357–359. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Kaern J, Tropé C, Sundfoer K and
Kristensen GB: Cisplatin/5-fluorouracil treatment of recurrent
cervical carcinoma: a phase II study with long-term follow-up.
Gynecol Oncol. 60:387–392. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kaern J, Tropé C, Abeler V, Iversen T and
Kjørstad K: A phase II study of 5-fluorouracil/cisplatinum in
recurrent cervical cancer. Acta Oncol. 29:25–28. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Benjapibal M, Thirapakawong C,
Leelaphatanadit C, Therasakvichya S and Inthasorn P: A pilot phase
II study of capecitabine plus cisplatin in the treatment of
recurrent carcinoma of the uterine cervix. Oncology. 72:33–38.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Daghestani N, Hakes TB, Lynch G and Lewis
JL Jr: Cervix carcinoma: treatment with combination cisplatin and
bleomycin. Gynecol Oncol. 16:334–339. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Coleman RE, Clarke JM, Slevin ML,
Sweetenham J, Williams CJ, Blake P, Calman F, Wiltshaw E and Harper
PG: A phase II study of ifosfamide and cisplatin chemotherapy for
metastatic or relapsed carcinoma of the cervix. Cancer Chemother
Pharmacol. 27:52–54. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Cervellino JC, Araujo CE, Sánchez O, Miles
H and Nishihama A: Cisplatin and ifosfamide in patients with
advanced squamous cell carcinoma of the uterine cervix. A phase II
trial. Acta Oncol. 34:257–259. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Burnett AF, Roman LD, Garcia AA,
Muderspach LI, Brader KR and Morrow CP: A phase II study of
gemcitabine and cisplatin in patients with advanced, persistent, or
recurrent squamous cell carcinoma of the cervix. Gynecol Oncol.
76:63–66. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Sugiyama T, Nishida T, Kumagai S, Nishio
S, Fujiyoshi K, Okura N, Yakushiji M, Hiura M and Umesaki N:
Combination therapy with irinotecan and cisplatin as neoadjuvant
chemotherapy in locally advanced cervical cancer. Br J Cancer.
81:95–98. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Sugiyama T, Yakushiji M, Noda K, Ikeda M,
Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji
F, Takahashi T, Umesaki N, Sato S, Hatae M and Ohashi Y: Phase II
study of irinotecan and cisplatin as first-line chemotherapy in
advanced or recurrent cervical cancer. Oncology. 58:31–37. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Rose PG, Blessing JA, Gershenson DM and
McGehee R: Paclitaxel and cisplatin as first-line therapy in
recurrent or advanced squamous cell carcinoma of the cervix: a
Gynecologic Oncology Group study. J Clin Oncol. 17:2676–2680.
1999.
|
|
120
|
Papadimitriou CA, Sarris K, Moulopoulos
LA, Fountzilas G, Anagnostopoulos A, Voulgaris Z, Gika D,
Giannakoulis N, Diakomanolis E and Dimopoulos MA: Phase II trial of
paclitaxel and cisplatin in metastatic and recurrent carcinoma of
the uterine cervix. J Clin Oncol. 17:761–766. 1999.PubMed/NCBI
|
|
121
|
Piver MS, Ghamande SA, Eltabbakh GH and
O’Neill-Coppola C: First-line chemotherapy with paclitaxel and
platinum for advanced and recurrent cancer of the cervix – a phase
II study. Gynecol Oncol. 75:334–337. 1999.
|
|
122
|
Long HJ III, Bundy BN, Grendys EC Jr,
Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA and Fiorica
JV: Randomized phase III trial of cisplatin with or without
topotecan in carcinoma of the uterine cervix: a Gynecologic
Oncology Group Study. J Clin Oncol. 23:4626–4633. 2005. View Article : Google Scholar
|
|
123
|
Monk BJ, Sill MW, McMeekin SD, Cohn DE,
Ramondetta LM, Boardman CH and Benda J: A randomized phase III
trial of four cisplatin (CIS) containing doublet combinations in
stage IVb, recurrent, or persistent cervical carcinoma: a
Gynecologic Oncology Group (GOG) study. J Clin Oncol. 26(Suppl
294): abs. LBA 5504. 2008.
|
|
124
|
Wenzel LN, Huang H, Cella D, Monk BJ, Sill
MW, McMeekin SD, Cohn DE, Ramondetta LM, Boardman CH and Benda J:
Quality-of-life results of a randomized phase III trial of four
cisplatin (Cis) containing doublet combinations in stage Ivb
cervical carcinoma: a Gynecologic Oncology Group (GOG) study. J
Clin Oncol. 26(Suppl 300): abs. 5529. 2008.
|
|
125
|
Bloss JD, Blessing JA, Behrens BC, Mannel
RS, Rader JS, Sood AK, Markman M and Benda J: Randomized trial of
cisplatin and ifosfamide with or without bleomycin in squamous
carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin
Oncol. 20:1832–1837. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Cadron I, Jakobsen A and Vergote I: Report
of an early stopped randomized trial comparing cisplatin vs.
cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer.
Gynecol Obstet Invest. 59:126–129. 2005.PubMed/NCBI
|
|
127
|
Zanetta G, Fei F, Parma G, Balestrino M,
Lissoni A, Gabriele A and Mangioni C: Paclitaxel, ifosfamide and
cisplatin (TIP) chemotherapy for recurrent or persistent
squamous-cell cervical cancer. Ann Oncol. 10:1171–1174. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Dimopoulos MA, Papadimitriou CA, Sarris K,
Aravantinos G, Kalofonos C, Gika D, Gourgoulis GM, Efstathiou E,
Skarlos D and Bafaloukos D: Combination of ifosfamide, paclitaxel,
and cisplatin for the treatment of metastatic and recurrent
carcinoma of the uterine cervix: a phase II study of the Hellenic
Cooperative Oncology Group. Gynecol Oncol. 85:476–482. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Choi CH, Kim TJ, Lee SJ, Lee JW, Kim BG,
Lee JH and Bae DS: Salvage chemotherapy with a combination of
paclitaxel, ifosfamide, and cisplatin for the patients with
recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer.
16:1157–1164. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Van Luijk IF, Coens C, van der Burg ME,
Kobierska A, Namer M, Lhomme C, Zola P, Zanetta G and Vermorken JB;
Gynecological Cancer Group of the European Organization for
Research and Treatment of Cancer. Phase II study of bleomycin,
vindesine, mitomycin C and cisplatin (BEMP) in recurrent or
disseminated squamous cell carcinoma of the uterine cervix. Ann
Oncol. 18:275–281. 2007.
|
|
131
|
Buda A, Fossati R, Colombo N, Fei F,
Floriani I, Gueli Alletti D, Katsaros D, Landoni F, Lissoni A,
Malzoni C, Sartori E, Scollo P, Torri V, Zola P and Mangioni C:
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel,
ifosfamide and cisplatin with ifosfamide and cisplatin followed by
radical surgery in patients with locally advanced squamous cell
cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio)
Italian Collaborative Study. J Clin Oncol. 23:4137–4145. 2005.
|
|
132
|
Mourton SM, Sonoda Y, Abu-Rustum NR,
Bochner BH, Barakat RR and Chi DS: Resection of recurrent cervical
cancer after total pelvic exenteration. Int J Gynecol Cancer.
17:137–140. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Bodurka-Bevers D, Morris M, Eifel PJ,
Levenback C, Bevers MW, Lucas KR and Wharton JT: Posttherapy
surveillance of women with cervical cancer: an outcome analysis.
Gynecol Oncol. 78:187–193. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Monk BJ, Sill MW, Burger RA, Gray HJ,
Buekers TE and Roman LD: Phase II trial of bevacizumab in the
treatment of persistent or recurrent squamous cell carcinoma of the
cervix: a gynecologic oncology group study. J Clin Oncol.
27:1069–1074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Coleman RL; Gynecologic Oncology Group’s.
The Gynecologic Oncology Group’s role in the treatment of recurrent
cervix cancer: current clinical trials. Gynecol Oncol. 110(Suppl
2): 77–80. 2008.
|
|
136
|
Bellone S, Frera G, Landolfi G, Romani C,
Bandiera E, Tognon G, Roman JJ, Burnett AF, Pecorelli S and Santin
AD: Overexpression of epidermal growth factor type-1 receptor
(EGF-R1) in cervical cancer: implications for Cetuximab-mediated
therapy in recurrent/metastatic disease. Gynecol Oncol.
106:513–520. 2007. View Article : Google Scholar
|
|
137
|
Goncalves A, Fabbro M, Lhommé C, Gladieff
L, Extra JM, Floquet A, Chaigneau L, Carrasco AT and Viens P: A
phase II trial to evaluate gefitinib as second- or third-line
treatment in patients with recurring locoregionally advanced or
metastatic cervical cancer. Gynecol Oncol. 108:42–46. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Del Campo JM, Prat A, Gil-Moreno A, Pérez
J and Parera M: Update on novel therapeutic agents for cervical
cancer. Gynecol Oncol. 110(Suppl 2): 72–76. 2008.PubMed/NCBI
|
|
139
|
Hindenburg AA and Matthews L: Complete and
sustained remission of refractory cervical cancer following a
single cycle of capecitabine. A case report. Int J Gynecol Cancer.
13:898–900. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Khoury-Collado F, Bowes RJ, Jhamb N,
Aghajanian C and Abu-Rustum NR: Unexpected long-term survival
without evidence of disease after salvage chemotherapy for
recurrent metastatic cervical cancer: a case series. Gynecol Oncol.
105:823–825. 2007. View Article : Google Scholar : PubMed/NCBI
|
